OMEGA PHARMA acquired by PERRIGO COMPANY
Context
Perrigo has completed the acquisition of Omega Pharma. This transaction acts as a massive "commercial accelerator," solving the complex logistical and regulatory barriers inherent in the European pharmacy landscape. By internalizing a sophisticated thirty-five-country distribution network, the group eliminates its dependency on regional third-party agents and secures immediate shelf-space for its expansive US-developed product pipeline. The strategic rationale hinges on the synergy between localized branding expertise and centralized manufacturing scale. While the acquirer provides the industrial backbone and cost-efficiency of a global supplier, the target brings the technical operational depth required to navigate diverse European healthcare systems and consumer preferences.
OMEGA PHARMA, which reported an EBITDA margin of [members only] in 2014, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Omega Pharma NV is a Belgian company of over-the-counter (OTC) healthcare solutions. The organization thrives on a philosophy of "pharmacist-focused" growth, prioritizing the development and commercialization of a vast portfolio of non-prescription products. Rather than specializing in a single therapeutic area, the firm utilizes a multi-category approach, maintaining leadership in cough and cold, skincare, pain relief, and weight management. Its value proposition is anchored in its extensive European commercial infrastructure, which facilitates direct relationships with pharmacy networks across dozens of countries. The entity's strategy is fueled by a disciplined brand-building mandate and an agile regulatory framework, ensuring rapid market entry for innovative self-care solutions.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2015 | WHITEWAVE | VEGA | CANADA | Nutrition & Dietary Supplements |
| 06/2015 | BC PARTNERS | PHARMATHEN | GREECE | CDMO |
| 11/2014 | QUALIUM | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2014 | INSTITUT MERIEUX / SAGARD / SOFIPROTEOL | CEVA SANTE ANIMALE | FRANCE | Animal Health |
| 03/2014 | MONTAGU PRIVATE EQUITY | Arkopharma | FRANCE | Nutrition & Dietary Supplements |
| 02/2014 | MONTAGU PRIVATE EQUITY | NEMERA | FRANCE | Medical Consumables |
| 01/2014 | FIVE ARROWS | DUTSCHER | FRANCE | Medical Consumables |
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
Other operations with PERRIGO COMPANY
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Generics / Labs |
| 02/2020 | PERRIGO COMPANY | HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO) | UNITED STATES | Generics / Labs |
| 08/2016 | PERRIGO COMPANY | GEISS DESTIN & DUNN (GDD) | UNITED STATES | B2B Specialized Distribution |
| 07/2015 | PERRIGO COMPANY | NATURWOHL PHARMA (YOKEBE) | GERMANY | Generics / Labs |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €1–10bn
EBITDA range: €250–500M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OMEGA PHARMA by PERRIGO COMPANY are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.